Skip to main content
OpenTrials
Completed

NCT Number: NCT05801991

Neurolens and Contact Lens Discomfort

The objective of this study is to determine how neurolens® influences contact lens discomfort in uncomfortable myopic soft contact lenses wearers. It is hypothesized that uncomfortable soft contact lens wearers are experiencing some level of discomfort associated with increased vergence demand when looking at near targets and will experience discomfort relief when wearing neurolens® over their habitual soft contact lenses. Uncomfortable, myopic soft contact lens wearers will be recruited. Each participant will be masked and randomly assigned a placebo pair of spectacles or a neurolens® spectacle pair for approximately one month. A prospective, randomized clinical trial will be performed. Participants and investigators will be masked to the treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Southern California College of Optometry at Marshall B. Ketchum University

Fullerton, California, 92831, United States

About this study

Discomfort is the primary reason for contact lens dissatisfaction and discontinuation. Symptoms of contact lens discomfort are often attributed to dryness; however, severity of dry eye and discomfort symptoms is not correlated with clinical dry eye severity. When clinical signs of contact lens discomfort and dryness misalign with symptom severity, the possibility of an under-recognized etiology must be considered.

Symptoms associated with contact lens discomfort are similar to symptoms reported with binocular vision disorders and accommodative and vergence strain. Eyestrain, fatigue, and increased/more frequent end-of-day symptoms are noted by patients in both groups of conditions. It has been reported that uncomfortable contact lens wearers have an unusually high prevalence of binocular vision disorders and clinical signs. Basic optical calculations show that myopes must converge and accommodate more when corrected with contact lenses versus spectacles, so it is reasonable to hypothesize that a myopic contact lens wearer may experience eyestrain and discomfort associated with vergence fatigue while wearing contact lenses, but not while wearing single vision spectacles.

neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision. This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer. Acknowledging that some amount of contact lens discomfort may be caused by vergence fatigue, it is possible that uncomfortable contact lens wearers who wear neurolens® over their contact lenses will achieve discomfort relief.

The objective of this study is to determine how neurolens® influences contact lens discomfort in uncomfortable myopic soft contact lenses wearers. Investigators hypothesize that uncomfortable soft contact lens wearers are experiencing some level of discomfort associated with increased vergence demand when looking at near targets and will experience discomfort relief when wearing neurolens® over their habitual soft contact lenses. Uncomfortable, myopic soft contact lens wearers will be recruited. Each participant will be masked and randomly assigned a placebo pair of spectacles or a neurolens® spectacle pair for approximately one month. A prospective, randomized clinical trial will be performed. Participants and investigators will be masked to the treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Uncomfortable soft contact lens wearers (CLDEQ-8 ≥ 17 points)
  • Adult, pre-presbyopic age range (18 - 35 years)
  • Visual acuity of 20/25 or better in each eye with habitual contact lenses
  • Soft, spherical or low toric, single vision soft contact lens wearer:
  • Habitual contact lens sphere power -0.75 D or more myopic
  • Habitual contact lens are spherical design or have 1.75 D or less of cylinder correction
  • Habitual soft contact lenses are single vision design
  • Valid contact lens prescription at the date of the baseline
  • No significant subjective over-refraction in either eye with habitual soft contact lenses
  • No significant subjective over-refraction in either eye with habitual soft contact lenses
  • Sphere: ≤ 0.50 D myopia, ≤ 0.50 D hyperopia
  • Cylinder: ≤ 0.75 D
  • Valid measurement on the neurolens® Measurement Device (nMD2)
  • A numerical neurolens value
  • No low Measurement Quality Index (MQI) < 0.8 or convergence excess

Exclusion criteria

  • History of ocular surgery
  • History of ocular disease, amblyopia, strabismus, or vision therapy
  • History of neurolens or prism spectacle correction
  • History of significant vertical phoria or vertical phoria correction
  • Current ocular medication use
  • Significant signs of dry eye:
  • > Grad 1 ocular surface staining
  • Schirmer scores < 7 mm
  • Tear break up time < 7 seconds
  • Signs of inappropriate fit or surface of soft contact lenses
  • Insufficient movement centration, and/or coverage
  • Significant lens deposits
  • Signs of corneal or conjunctival contact-lens related complications

Treatment and study plan

Neurolens

Device

neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.

Placebo spectacle lens

Device

Plano (no power) spectacle lenses will be assigned to the placebo group

Primary outcomes

  1. Change in Contact Lens Discomfort

    Time frame: Baseline and 30-35 days

    Change in contact lens discomfort measured by the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8), Score range: 0 - 37 points, Higher scores indicate worse symptoms

Secondary outcomes

  1. Change in Convergence Insufficiency Symptoms

    Time frame: Baseline and 30-35 days

    Change in convergence insufficiency symptoms measured by the Convergence Insufficiency Symptom Survey (CISS), Score range 0 - 60 points, Higher scores indicate worse symptoms

  2. Change in Headache Symptoms

    Time frame: Baseline and 30-35 days

    Change in headache symptoms measured by the Headache Impact Test (HIT-6), Score range: 36 - 78 points, Higher scores indicate worse symptoms

  3. Change in Dry Eye Symptoms

    Time frame: Baseline and 30-35 days

    Change in dry eye symptoms measured by the Standard Patient Evaluation of Eye Dryness (SPEED) survey, Score range: 0 - 28 points, Higher scores indicated worse symptoms

Sponsors and collaborators

Lead sponsor

Southern California College of Optometry at Marshall B. Ketchum University

Other

Collaborators

  • Neurolens Inc.

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 6, 2023
Registry last updated
Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.